Bharat Biotech’s Nucelion Partners with Pandorum for Exosome Therapy

Hyderabad, India, 6th January 2026 : Pandorum Technologies, a clinical-stage regenerative medicine company, has announced a strategic collaboration with Nucelion Therapeutics, a Hyderabad-based contract research, development, and manufacturing organization (CRDMO). The partnership aims to enhance manufacturing capabilities for Pandorum’s exosome-based therapeutic platform in the Asia-Pacific (APAC) region, with a focus on ocular diseases.

The collaboration will support Pandorum’s efforts as it progresses its exosome-based therapies toward clinical trials. By leveraging Nucelion’s advanced manufacturing infrastructure, the partnership will help address regional supply and regulatory requirements, marking a significant step in the development of next-generation biologic therapies in India.

“Pandorum is building a global regenerative medicine platform designed for scale, consistency, and partnership,” said Dr. Tuhin Bhowmick, PhD, CEO of Pandorum Technologies. “Nucelion’s expertise in biologics manufacturing is crucial for our programs as they move closer to clinical and commercial milestones. This partnership ensures we can deliver high-quality, programmable exosome therapies to patients globally.”

The partnership will initially focus on Pandorum’s therapies for ocular diseases, including ocular surface injury and inflammatory corneal conditions like Stevens–Johnson syndrome (SJS) and Neurotrophic Keratitis. The company also plans to expand its reach to treat other diseases involving inflammation, vascular pathologies, and fibrosis in organs such as skin and lungs.

India’s Pandorum, Bharat Biotech’s Nucelion Advances Regenerative Medicine for Ocular Disease

Dr. Raghu Malapaka, PhD, CBO of Nucelion Therapeutics, expressed enthusiasm about the collaboration. “We’re excited to support the scalable production of Pandorum’s designer exosome-based therapies. Our advanced manufacturing platforms are well-suited to support complex biologics, and we look forward to contributing to the treatment of ocular diseases in the APAC region.”

The collaboration signals India’s growing capability to develop and manufacture cutting-edge biologic therapies, with support from the government and organizations like BIRAC. Dr. Jitendra Kumar, Managing Director of BIRAC, noted, “This partnership between Pandorum and Nucelion underscores India’s readiness to innovate and produce for global clinical needs.”

Kuragenx- the ‘Liquid’ Cornea

Kuragenx is Pandorum Technologies Ocular Therapy platform product that can reverse an ulcerative cornea to a healthy state in less than a year, which is in advance clinical trials.

Nucelion Therapeutics is a subsidiary of Bharat Biotech, a global leader in vaccine and biotechnology development. The company will provide comprehensive support, including process scale-up, GMP-compliant production, and quality control for the exosomes derived from clinical-grade mesenchymal stem cells.

Pandorum’s proprietary exosome platform is designed to restore tissue structure and function by modulating intercellular communication pathways. The technology holds promise for a wide range of conditions driven by inflammation, fibrosis, and a loss of regenerative capacity.